Locations:
Search IconSearch
April 20, 2017/Cancer

Study Examines Effectiveness and Accuracy of Prostate Cancer Prognostication

Could a new risk-stratification system improve decision-making?

650×450-McKenney Prostate

It might be worth a second look at the pathology report for that man with a Gleason score 3+4=7 who just elected active surveillance. Then again, he may be preparing for radical prostatectomy despite having indolent disease that is unlikely to progress.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

These apprehensions and second guesses regularly plague urologists and other providers—and for good reason. Men with Gleason scores of 3+4=7 (grade group 2) have increasingly become candidates for active surveillance, but the current grading system is inadequate to account for many structural variations of prostate cancer histology.

Gleason can under- and over-diagnose

A recent study in the American Journal of Surgical Pathology, led by Cleveland Clinic anatomic pathologist Jesse McKenney, MD, provides a detailed accounting of the various histological patterns in prostate cancer and matches them with prognostic clinical outcomes.

“This study shows several histological patterns where the current Gleason system misses patients with aggressive cancers,” says Dr. McKenney. “Simultaneously, we identified structures where patients had more indolent disease and were likely over-graded.”

The study included 1,275 patients from the Canary radical prostatectomy cohort. Dr. McKenney’s team put tissue samples from prostatectomy under the microscope in an unbiased environment to evaluate their architecture without prior knowledge of the patients’ pathology reports.

They classified the various architectures, placed them into the traditional Gleason scoring system, compared and ranked their relative prognostic predictive strengths, and then offered analysis of where the current system falls short.

Altogether, the study team evaluated the relative prognostic strength of 21 distinct histological architectures based on their ability to predict clinical outcomes. A detailed accounting of the patterns, including visuals, frequency and links to clinical outcomes appears in the published study.

Advertisement

Their results show that 25 percent of patients on active surveillance have architectural patterns in their tumors that could have potentially changed the overall Gleason score (i.e., Gleason score 3+3=6 vs. 3+4=7) depending on a pathologist’s individual diagnostic threshold.

Furthermore, among men who are rightly classified as having Gleason grade 4 disease, there are diverse variations predictive of clinical outcomes and disease aggressiveness.

Histology reclassified

Comparison of tumor histology to long-term clinical outcomes among men in the study cohort revealed three noteworthy and frequent patterns that could better inform treatment decisions:

  • Cribiform patterns, which signify more aggressive disease
  • Stromogenic carcinoma, which signifies more aggressive disease
  • Extravasated mucin, which signifies less aggressive disease

Study data suggest that focal poorly formed gland and cribriform patterns, currently classified as Gleason pattern 4, should be in separate prognostic groups, as the latter is associated with worse outcome.

Patterns with extravasated mucin are likely overgraded in a subset of cases with more complex epithelial bridges, whereas stromogenic cancers have a worse outcome than conveyed by Gleason grade alone.

A better risk-stratification system?

Ultimately, the goal is to create a histological risk-stratification system that pathologists can use to further personalize medicine that does not add additional healthcare costs and that can be applied worldwide in any setting regardless of available resources.

“My hope is that ultimately all of this information will be incorporated into grading system standards so that we can more accurately characterize the aggressiveness of prostate cancer and allow urologists to make more informed decisions,” Dr. McKenney says.

Advertisement

805x-Inset-McKenney Prostate

Example of mucinous fibroplasia in prostate cancer histology. A study by Jesse McKenney, MD, and collaborators places this subtype of disease along a broad spectrum that has not been previously addressed. Data from this study suggest that cancers with mucin rupture have a relatively low risk of recurrence after prostatectomy and may be a frequent source of cancer over-grading and over treatment.

Advertisement

Related Articles

Oncologist consulting with couple
April 29, 2025/Cancer/News & Insight
Are Your Patients With Cancer Experiencing Sexual Dysfunction? Just Ask!

Sexual disorders affect patients across all cancer types

Dr. Khorana
April 25, 2025/Cancer/News & Insight
Molecular Insights into Early-Onset Biliary Tract Cancer (Podcast)

A call for awareness about the importance of genomic testing

Dr. Melenhorst
April 24, 2025/Cancer/News & Insight
Explore Developments in CAR T-Cell Therapy for CLL (Podcast)

Discussing research into improving CAR T-cell therapy efficacy

Dr. Cherian
April 23, 2025/Cancer/News & Insight
De-intensifying Radiation Therapy in Low-Risk Breast Cancer

Ultra-Hypofractionated Whole Breast Irradiation and Partial Breast Irradiation Reduce Many Toxicities

Pathology image
April 22, 2025/Cancer/News & Insight
Patient Case Study: Second Opinion Reveals Misdiagnosed Cancer

Patient receives liver transplant and a new lease on life

Clinician talking with patient
April 21, 2025/Cancer/News & Insight
Hematology Clinic Created to Support Spanish-Speaking Population

Lutheran Hospital team brings emerging treatments to community setting

Dr. Pennell and patient
April 10, 2025/Cancer/News & Insight
BiTE Therapy Emerges for Treating Small-Cell Lung Cancer

Hybrid treatment model helps improve cancer care access

Immune checkpoint inhibitor illustration
April 8, 2025/Cancer
Building on Initial Trial Data about New Immune Checkpoint Inhibitor for Treating Colorectal Cancer

Insights indicate that treatment may be beneficial beyond MSI-H tumors

Ad